MTNB
$0.93
Matinas Biopharma Hl
($.10)
(9.71%)
MTNB
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.03)
Revenue:  $0.10 Mil
Monday
Feb 7
6:35 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MTNB reports earnings?
Beat
Meet
Miss

Where is MTNB's stock price going from here?
Up
Flat
Down
Stock chart of MTNB
Analysts
Summary of analysts' recommendations for MTNB
Score
Grade
Pivots
Resistance
$1.10
$1.06
$0.99

$0.95

Support
$0.88
$0.84
$0.77
Tweet
Growth
Description
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept